Replies to post #68597 on Biotech Values

[ghmm]

Thanks to Bladerunner for a couple of additions to the list (I guess the format I chose is not the easieast) and apljack for the correction.

[nuere]

Late Stage Products looking for a home

EDITS: Added Zybrestat, OXGN

Criteria
1. Unparterned
2. Not enough cash to bring the product to market
3. Lets say at least started Phase 3 trials
4. Its on a product basis so if company a has 2 unparterned Phase 3 products and not enough cash then an entry for each would be appropriate

 
 Stock  Product          Stage                   Comments   
 -----  ---------------  ---------------------   -----------------------------   
 NTII   Viprinex         Phase 3                 Interim analysis January '09.  Stroke Drug, high chance of failure.   
 BPAX   Libigel          Phase 3 ~2010 Submit    Adequate Safety?   
 EPIX   Vasovist         PDUFA 12/30/08          FDA initially rejected saying 2 more studies needed.  Allowed reread company states   
                                                 results very positive.  Looking to sell outright on approval.   
 RPRX   Proellex         Phase 3                 Uterine fibroids   
 CHTP   Droxidopa        Pivotal Phase III       Orthostatic hypotension.  Results expected 02/09 
 JAV    Dyloject         Phase III               Approved in UK.  Post operative Pain (injectable) 
 JAV    Ketamine         Phase III               Acute moderate-to-severe pain (intranasal) 
 GNVC   TNFerade         Pivotal Phase III       Pancreatic cancer  
 OXGN   Zybrestat        Phase 3                 Anaplastic thyroid cancer 
 

-----
Updating the list
1. Reply to this post copying all the text
2. Changed the "EDITS:" to account for changes, e.g. Edits: Added Viprinex
3. Please put [ pre ] at the begining of the table without surrounding spaces are "pre".
4. Please put [ /pre ] at the end of the table without surrounding spaces around "pre".